Crispr Therapeutics (CRSP) Stock Price
$37.28 2%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
7 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Crispr Therapeutics, AI stock picks, stock alerts and much more.
CRSP AI Stock Analysis
AI stock analysis for CRSP is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Crispr Therapeutics (CRSP) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Crispr Therapeutics (CRSP) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Crispr Therapeutics (CRSP), currently trading at $37.28, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About CRSP
-
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
-
Symbol
CRSP
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
3.2B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$24.7 0.6% |
4 |
 |
Inovio Pharmaceuticals INO |
$1.71 2.8% |
1 |
 |
Moderna MRNA |
$31.16 3% |
3 |
 |
Anavex Life Sciences AVXL |
$8.77 8.1% |
5 |
 |
BridgeBio Pharma BBIO |
$35.3 3% |
5 |
News
CRSP Alternative Data
Web Traffic
Crispr Therapeutics receives an estimated 105901 monthly visitors to crisprtx.com.
-
Web Traffic
105901
-
Change from Previous Month
17.4%
-
3 Month Change
19.2%
-
YoY Change
19.2%
News Mentions
Crispr Therapeutics was mentioned 2 times in the news yesterday.
-
News Mentions
2
-
Daily Change
66.7%
-
1 Month Change
0%
-
3 Month Change
66.7%
Reddit Mentions
Crispr Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
100%
Twitter Followers
Crispr Therapeutics has 22,433 Twitter Followers on its main Twitter (also known as X) account, which is up by 0% over the last month.
-
Twitter Followers
22433
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.7%
-
YoY Change
0.7%
LinkedIn Followers
99,091 are following Crispr Therapeutics on LinkedIn, up by 0.4% over the last month.
-
LinkedIn Followers
99091
-
Daily Change
0%
-
1 Month Change
0.4%
-
3 Month Change
1.2%
Job Postings
Crispr Therapeutics currenly has an estimated 2 open job postings, up by 100% over the last month.
-
Job Postings
2
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
66.7%
-
YoY Change
66.7%
LinkedIn Employees
According to LinkedIn, Crispr Therapeutics has 440 employees.
-
LinkedIn Employees
440
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Crispr Therapeutics is 46 out of 100 (neutral).
-
Business Outlook
46
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
CRSP Financials
CRSP Key Metrics
-
Total Revenue
$35M
-
Net Income
-$37.3M
-
Earnings per Share
-$0.44
-
Free cash flow
-$50.3M
-
EBITDA
-$59.7M
-
EBITDA Ratio
-1.70703
-
Total Assets
$2.2B
CRSP 2-year Revenue & Income
CRSP 2-year Free Cash Flow
CRSP Technicals
CRSP SMA
CRSP RSI
FAQ
What's the current price of Crispr Therapeutics (CRSP) Stock?
The price of an Crispr Therapeutics (CRSP) share is $37.28.
What's the market cap of Crispr Therapeutics?
The current market cap of Crispr Therapeutics is 3.2B.
Should I buy or sell CRSP?
Crispr Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Crispr Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Crispr Therapeutics a good investment?
The current analysis of Crispr Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Crispr Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Crispr Therapeutics (CRSP) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Crispr Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Crispr Therapeutics (CRSP) that investors often compare it to?
Crispr Therapeutics (CRSP) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Crispr Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Crispr Therapeutics' stock price to be around $38.38 in 2026. Starting from the current price of $37.28, this represents a 2.9% change in price, indicating a neutral outlook for the stock.
How to buy Crispr Therapeutics (CRSP) Stock?
Crispr Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Crispr Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.